Exelixis, INC.
Oncology-focused biotechnology company
Based in CA
🤖
AI Overview
With $1.5M in lobbying spend across 23 quarterly filings, Exelixis, INC. is a significant lobbying presence. They deploy 12 individual lobbyists
$1.5M
Total Lobbying Spend
23
Quarterly Filings
1
Lobbying Firms Used
12
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $20K |
| 2019 | $250K |
| 2020 | $200K |
| 2021 | $180K |
| 2022 | $180K |
| 2023 | $300K |
| 2024 | $180K |
| 2025 | $180K |
Lobbying Firms
ARNOLD & PORTER KAYE SCHOLER LLP
What They Lobby For
- Issues related to access, coverage, and payment for cancer drugs.
- Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. CREATES Act of 2019 (S. 340/H.R. 965). Lower Health Care Costs Act (S. 1895).
- Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Prescription Drug Pricing Reduction Act (S. 2543). Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3).
- Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. Lower Health Care Costs Act (S. 1895).
- Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19).
- Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
- Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); H.R.5376, the Build Back Better Act.
- Issues related to R&D tax credits.
- Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); Build Back Better Act (H.R. 5376); and the Inflation Reduction Act (H.R. 5376).
- Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169).
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Who's Lobbying to Shape AI Policy
The AI regulation fight is the biggest lobbying battle of the decade.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.